HUTCHMED (China) (HCM) Stock Forecast, Price Target & Predictions
HCM Stock Forecast
HUTCHMED (China) stock forecast is as follows: an average price target of $17.50 (represents a 22.29% upside from HCM’s last price of $14.31) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
HCM Price Target
The average price target for HUTCHMED (China) (HCM) is $17.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $17.50 to $17.50. This represents a potential 22.29% upside from HCM's last price of $14.31.
HCM Analyst Ratings
According to 6 Wall Street analysts, HUTCHMED (China)'s rating consensus is 'Buy'. The analyst rating breakdown for HCM stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
HUTCHMED (China) Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Jack Lin | Morgan Stanley | $17.50 | $21.45 | -18.41% | 22.29% |
The latest HUTCHMED (China) stock forecast, released on May 14, 2024 by Jack Lin from Morgan Stanley, set a price target of $17.50, which represents a -18.41% decrease from the stock price at the time of the forecast ($21.45), and a 22.29% increase from HCM last price ($14.31).
HUTCHMED (China) Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $17.50 |
| Last Closing Price | $14.31 | $14.31 | $14.31 |
| Upside/Downside | -100.00% | -100.00% | 22.29% |
In the current month, the average price target of HUTCHMED (China) stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to HUTCHMED (China)'s last price of $14.31. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 23, 2024 | Goldman Sachs | Buy | Buy | Hold |
| May 29, 2024 | HSBC | Buy | Initialise | |
| May 14, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Nov 23, 2023 | Deutsche Bank | Buy | Upgrade | |
| Nov 10, 2023 | Goldman Sachs | Neutral | Neutral | Hold |
| Mar 02, 2023 | Needham | Buy | Buy | Hold |
| Mar 02, 2023 | Craig-Hallum | Buy | Buy | Hold |
| Aug 09, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
HUTCHMED (China)'s last stock rating was published by Goldman Sachs on Aug 23, 2024. The company gave HCM a "Buy" rating, the same as its previous rate.
HUTCHMED (China) Financial Forecast
HUTCHMED (China) Revenue Forecast
| Jun 28 | Mar 28 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $379.31M | $358.38M | $318.48M | $307.93M | $210.04M | $175.22M | $90.66M | $80.92M | $90.66M | $57.28M | $49.94M | $47.25M | $47.25M | $53.62M | $319.35M | $53.62M |
| High Forecast | $379.31M | $358.38M | $318.48M | $307.93M | $210.04M | $175.22M | $90.66M | $80.92M | $92.36M | $57.28M | $49.94M | $47.25M | $47.25M | $53.62M | $319.35M | $56.79M |
| Low Forecast | $379.31M | $358.38M | $318.48M | $307.93M | $210.04M | $175.22M | $90.66M | $80.92M | $88.97M | $57.28M | $49.94M | $47.25M | $47.25M | $53.62M | $319.35M | $47.39M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
HUTCHMED (China)'s average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. HCM's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
HUTCHMED (China) EBITDA Forecast
| Jun 28 | Mar 28 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-224.24M | $-211.87M | $-188.28M | $-182.04M | $-124.17M | $-103.59M | $-53.60M | $-47.84M | $-53.60M | $-33.86M | $-29.52M | $-27.93M | $-27.93M | $-31.70M | $-188.79M | $-31.70M |
| High Forecast | $-224.24M | $-211.87M | $-188.28M | $-182.04M | $-124.17M | $-103.59M | $-53.60M | $-47.84M | $-52.60M | $-33.86M | $-29.52M | $-27.93M | $-27.93M | $-31.70M | $-188.79M | $-28.02M |
| Low Forecast | $-224.24M | $-211.87M | $-188.28M | $-182.04M | $-124.17M | $-103.59M | $-53.60M | $-47.84M | $-54.60M | $-33.86M | $-29.52M | $-27.93M | $-27.93M | $-31.70M | $-188.79M | $-33.58M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict HCM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than HUTCHMED (China)'s previous annual EBITDA (undefined) of $NaN.
HUTCHMED (China) Net Income Forecast
| Jun 28 | Mar 28 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $52.35M | $-52.35M | $-479.89M | $-453.72M | $-1.07B | $-889.99M | $-294.96M | $-312.42M | $-294.96M | $-276.55M | $-114.35M | $-144.43M | $-144.43M | $-113.43M | $-342.03M | $-113.43M |
| High Forecast | $52.35M | $-52.35M | $-479.89M | $-453.72M | $-1.07B | $-889.99M | $-294.96M | $-312.42M | $-294.96M | $-276.55M | $-114.35M | $-144.43M | $-144.43M | $-113.43M | $-342.03M | $-113.43M |
| Low Forecast | $52.35M | $-52.35M | $-479.89M | $-453.72M | $-1.07B | $-889.99M | $-294.96M | $-312.42M | $-294.96M | $-276.55M | $-114.35M | $-144.43M | $-144.43M | $-113.43M | $-342.03M | $-113.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
HUTCHMED (China)'s average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HCM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
HUTCHMED (China) SG&A Forecast
| Jun 28 | Mar 28 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $103.36M | $97.66M | $86.79M | $83.91M | $57.24M | $47.75M | $24.71M | $22.05M | $24.71M | $15.61M | $13.61M | $12.88M | $12.88M | $14.61M | $87.02M | $14.61M |
| High Forecast | $103.36M | $97.66M | $86.79M | $83.91M | $57.24M | $47.75M | $24.71M | $22.05M | $25.17M | $15.61M | $13.61M | $12.88M | $12.88M | $14.61M | $87.02M | $15.48M |
| Low Forecast | $103.36M | $97.66M | $86.79M | $83.91M | $57.24M | $47.75M | $24.71M | $22.05M | $24.24M | $15.61M | $13.61M | $12.88M | $12.88M | $14.61M | $87.02M | $12.92M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
HUTCHMED (China)'s average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to HCM last annual SG&A of $NaN (undefined).
HUTCHMED (China) EPS Forecast
| Jun 28 | Mar 28 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $0.06 | $-0.06 | $-0.55 | $-0.52 | $-1.23 | $-1.02 | $-0.34 | $-0.36 | $-0.34 | $-0.32 | $-0.13 | $-0.17 | $-0.17 | $-0.13 | $-0.39 | $-0.13 |
| High Forecast | $0.06 | $-0.06 | $-0.55 | $-0.52 | $-1.23 | $-1.02 | $-0.34 | $-0.36 | $-0.34 | $-0.32 | $-0.13 | $-0.17 | $-0.17 | $-0.13 | $-0.39 | $-0.13 |
| Low Forecast | $0.06 | $-0.06 | $-0.55 | $-0.52 | $-1.23 | $-1.02 | $-0.34 | $-0.36 | $-0.34 | $-0.32 | $-0.13 | $-0.17 | $-0.17 | $-0.13 | $-0.39 | $-0.13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, HUTCHMED (China)'s projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HCM previous annual EPS of $NaN (undefined).
HUTCHMED (China) Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $3.69 | $10.00 | 171.00% | |
| IRWD | Ironwood Pharmaceuticals | $3.53 | $8.50 | 140.79% | Buy |
| ANIP | ANI Pharmaceuticals | $55.83 | $79.00 | 41.50% | Buy |
| COLL | Collegium Pharmaceutical | $30.90 | $42.33 | 36.99% | Buy |
| ALKS | Alkermes | $30.75 | $37.50 | 21.95% | Hold |
| PCRX | Pacira BioSciences | $19.83 | $23.75 | 19.77% | Hold |
| HCM | HUTCHMED (China) | $14.86 | $17.50 | 17.77% | Buy |
| PBH | Prestige Consumer Healthcare | $80.39 | $89.50 | 11.33% | Buy |
| ITCI | Intra-Cellular Therapies | $86.96 | $93.33 | 7.33% | Buy |
| PAHC | Phibro Animal Health | $22.34 | $18.67 | -16.43% | Buy |